NCT04929028 2026-03-18Therapy Adapted for High Risk and Low Risk HIV-Associated Anal CancerNational Cancer Institute (NCI)Phase 2 Recruiting40 enrolled
NCT06770582 2026-03-18Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC TrialNational Cancer Institute (NCI)Phase 2 Recruiting160 enrolled